Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.

Biotechnology

Life Sciences

Therapeutics

Corner Therapeutics

Steven Altschuler

Jonathan Kagan

Jeff Karp

Andrew Bellinger

Andrew Cornforth

Laura Brandano

Sivan Elloul

Leadership Team

Research and Development

Operations Team

Teams at Corner Therapeutics

Leadership Team

Research and Development

Operations Team